MCID: MLG064
MIFTS: 41

Malignant Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Malignant Ependymoma

MalaCards integrated aliases for Malignant Ependymoma:

Name: Malignant Ependymoma 12 15
Ependymal Neoplasm 12 17
Ependymal Tumors 12 54
Experimental Organism Malignant Ependymoma 71
Anaplastic Ependymoma 71
Ependymoma of Brain 71
Ependymal Tumor 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5074
NCIt 49 C6770
UMLS 71 C0238029 C0280788 C1333407 more

Summaries for Malignant Ependymoma

Disease Ontology : 12 A malignant glioma that is derived from ependymal cells, a type of glial cell, located in ventricle lining within the central part of the brain.

MalaCards based summary : Malignant Ependymoma, also known as ependymal neoplasm, is related to spinal cord ependymoma and glioma susceptibility 1, and has symptoms including seizures, vomiting and headache. An important gene associated with Malignant Ependymoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways are Spinal Cord Injury and Glioblastoma Multiforme. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include ventricle lining, brain and spinal cord, and related phenotypes are Decreased p24 protein expression and respiratory system

Related Diseases for Malignant Ependymoma

Diseases in the Benign Ependymoma family:

Malignant Ependymoma Malignant Adult Ependymoma

Diseases related to Malignant Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 122)
# Related Disease Score Top Affiliating Genes
1 spinal cord ependymoma 31.8 YAP1 RELA NF2 NELL2 FAM118B C11orf95
2 glioma susceptibility 1 31.5 MGMT IDH1 GFAP EGFR
3 cellular ependymoma 31.4 RELA C11orf95
4 benign ependymoma 30.7 NF2 MGMT GFAP EGFR
5 anaplastic ependymoma 30.7 RELA NF2 GFAP
6 angiocentric glioma 30.4 IDH1 GFAP
7 clear cell ependymoma 30.3 IDH1 GFAP C11orf95
8 oligodendroglioma 29.7 MGMT IDH1 GFAP EGFR
9 myxopapillary ependymoma 29.5 YAP1 RELA PLA2G5 NF2 KRT75 GFAP
10 mixed glioma 29.4 MGMT IDH1 GFAP EGFR
11 supratentorial primitive neuroectodermal tumor 29.4 IDH1 GFAP
12 juvenile pilocytic astrocytoma 29.4 MGMT KIAA1549 IDH1 GFAP
13 meningioma, familial 28.8 NF2 MGMT KIAA1549 IDH1 GFAP EGFR
14 glial tumor 11.6
15 subependymal glioma 11.3
16 brain ependymoma 11.3
17 rela fusion-positive ependymoma 10.5 RELA C11orf95
18 suprasellar meningioma 10.5 NF2 GFAP
19 brain meningioma 10.5 YAP1 NF2
20 chordoid meningioma 10.4 NF2 GFAP
21 tanycytic ependymoma 10.4 NF2 KRT75 GFAP
22 rhabdoid meningioma 10.4 NF2 GFAP
23 oligoastrocytoma 10.4 MGMT GFAP
24 malignant peritoneal mesothelioma 10.3 NF2 EGFR
25 extraventricular neurocytoma 10.3 IDH1 GFAP
26 chordoid glioma 10.3 NF2 GFAP
27 cranial nerve neoplasm 10.3 NF2 GFAP
28 gliofibroma 10.2 KIAA1549 GFAP
29 pediatric supratentorial ependymoma 10.2 RELA MAMLD1 KRT75 C11orf95
30 pediatric meningioma 10.2 NF2 KIAA1549
31 neuroma 10.2 NF2 MGMT GFAP
32 optic nerve neoplasm 10.2 NF2 KIAA1549
33 frontal convexity meningioma 10.2 NF2 IDH1 GFAP
34 optic nerve glioma 10.1 NF2 KIAA1549 GFAP
35 clear cell meningioma 10.1 NF2 GFAP
36 adult brain stem glioma 10.1 MGMT IDH1
37 neurofibromatosis, type ii 10.1 YAP1 NF2 EGFR
38 temporal lobe neoplasm 10.1 MGMT IDH1
39 astrocytoma 10.1
40 subependymoma 10.1
41 gangliocytoma 10.1 KIAA1549 GFAP
42 gemistocytic astrocytoma 10.0 MGMT IDH1 GFAP
43 medulloblastoma 10.0
44 papilloma of choroid plexus 10.0
45 squamous cell papilloma 10.0
46 papilloma 10.0
47 medulloepithelioma 10.0
48 glioma 10.0
49 gliomatosis cerebri 10.0 IDH1 GFAP EGFR
50 adult oligodendroglioma 10.0 KIAA1549 IDH1

Graphical network of the top 20 diseases related to Malignant Ependymoma:



Diseases related to Malignant Ependymoma

Symptoms & Phenotypes for Malignant Ependymoma

UMLS symptoms related to Malignant Ependymoma:


seizures, vomiting, headache, nausea

GenomeRNAi Phenotypes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased p24 protein expression GR00163-A-1 8.92 EGFR IDH1 NF2 RELA

MGI Mouse Phenotypes related to Malignant Ependymoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.23 CBY1 CD207 EGFR IDH1 MGMT NF2

Drugs & Therapeutics for Malignant Ependymoma

Drugs for Malignant Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
4
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
5
Etoposide Approved Phase 3 33419-42-0 36462
6
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
11 Analgesics Phase 3
12 Cholinesterase Inhibitors Phase 3
13 Cholinergic Agents Phase 3
14 Liver Extracts Phase 3
15 Cola Phase 3
16 Anesthetics Phase 3
17 Narcotics Phase 3
18 Analgesics, Opioid Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Etoposide phosphate Phase 3
22 Immunosuppressive Agents Phase 3
23 Tubulin Modulators Phase 3
24 Antirheumatic Agents Phase 3
25 Antimitotic Agents Phase 3
26 Dermatologic Agents Phase 3
27 Podophyllotoxin Phase 3 518-28-5
28 Keratolytic Agents Phase 3
29 Neurotransmitter Agents Phase 3
30 Dopamine Agents Phase 3
31 Central Nervous System Stimulants Phase 3
32 Dexmethylphenidate Hydrochloride Phase 3
33
Ethanol Approved Phase 1, Phase 2 64-17-5 702
34
Pregabalin Approved, Investigational Phase 2 148553-50-8 5486971
35
Levetiracetam Approved Phase 2 102767-28-2 441341
36
Sodium citrate Approved, Investigational Phase 2 68-04-2
37
Tamoxifen Approved Phase 2 10540-29-1 2733526
38
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
41
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
42
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
43
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
44
leucovorin Approved Phase 2 58-05-9 6006 143
45
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
48
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
49
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
50
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Active, not recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine
4 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
5 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
6 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
7 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
8 A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
9 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
10 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
11 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
12 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
13 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
14 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
15 Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00352521 Phase 2 bevacizumab;irinotecan
16 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
17 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
18 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
19 Phase I Study of Intra-Tumoral, Radiolabeled, Anti-Tenascin Monoclonal Antibody 81C6 in the Treatment of Patients With Malignant Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
20 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
21 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
22 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
23 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
24 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
25 A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
26 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
27 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
28 Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Recruiting NCT03727841 Phase 2 Marizomib
29 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
30 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Active, not recruiting NCT02155920 Phase 2 Everolimus
31 Phase II Trial of Ritonavir/Lopinavir in Patients With Progressive of Recurrent High-Grade Gliomas Terminated NCT01095094 Phase 2 ritonavir;lopinavir
32 Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
33 Defining Functional Tissue in Brain Tumors With Integrated Neuroimaging (Pilot Study) Withdrawn NCT00005083 Phase 2
34 Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
35 Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
36 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
37 Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration Completed NCT00401024 Phase 1 imatinib mesylate
38 PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA Completed NCT00004028 Phase 1 carmustine
39 PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS Completed NCT00002753 Phase 1
40 A Phase I Study of Extended Low Dose Temozolomide (SCH 52365, Temodar (R)) and Carmustine (BCNU) in the Treatment of Malignant Gliomas After Radiation Therapy Completed NCT00005637 Phase 1 carmustine;temozolomide
41 A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas Completed NCT00036894 Phase 1 lenalidomide
42 Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea Completed NCT00387933 Phase 1 hydroxyurea;imatinib mesylate;vatalanib
43 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
44 Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease Completed NCT00025558 Phase 1 carboplatin;temozolomide;thiotepa
45 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
46 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
47 A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment Completed NCT01480050 Phase 1 temozolomide;Mibefradil
48 A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
49 A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors Completed NCT00544284 Phase 1 bortezomib;temozolomide
50 A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carboplatin in Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin

Search NIH Clinical Center for Malignant Ependymoma

Genetic Tests for Malignant Ependymoma

Anatomical Context for Malignant Ependymoma

The Foundational Model of Anatomy Ontology organs/tissues related to Malignant Ependymoma:

19
Ventricle Lining

MalaCards organs/tissues related to Malignant Ependymoma:

40
Brain, Spinal Cord, T Cells, Liver, Pineal, Bone, Bone Marrow

Publications for Malignant Ependymoma

Articles related to Malignant Ependymoma:

(show top 50) (show all 190)
# Title Authors PMID Year
1
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. 61 54
10433955 1999
2
Expression of glial fibrillary acidic protein, vimentin, fibronectin, and N-myc oncoprotein in primary human brain tumor cell explants. 61 54
1668298 1991
3
Advantage of high b value diffusion-weighted imaging for differentiation of common pediatric brain tumors in posterior fossa. 61
32438259 2020
4
cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. 61
32502305 2020
5
Proteomics of pediatric ependymomas: a review. 61
32377827 2020
6
Molecular characterization of histopathological ependymoma variants. 61
31679042 2020
7
Genomic Molecular Classification of CNS Malignancies. 61
31714292 2020
8
Fluorescein-guided surgery for spinal gliomas: Analysis of 220 consecutive cases. 61
32448604 2020
9
Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. 61
31595628 2020
10
MYCN amplification drives an aggressive form of spinal ependymoma. 61
31414211 2019
11
Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience. 61
31827999 2019
12
Adult Primary Brain Neoplasm, Including 2016 World Health Organization Classification. 61
31582041 2019
13
Detecting the long non‑coding RNA signature related to spinal cord ependymal tumor subtype using a genome‑wide methylome analysis approach. 61
31257484 2019
14
Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China. 61
31324163 2019
15
Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. 61
30325077 2019
16
Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012. 61
30984908 2019
17
Survival of infants ≤24 months of age with brain tumors: A population-based study using the SEER database. 61
31553771 2019
18
Subpial Cervical Subependymoma: Report of an Unusual Tumor with Review of Literature. 61
30937068 2019
19
Can apparent diffusion coefficient values help distinguish between different types of pediatric brain tumors? 61
30627595 2019
20
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. 61
30514397 2018
21
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. 61
30053291 2018
22
Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014. 61
29850889 2018
23
Advantages of high b-value diffusion-weighted imaging for preoperative differential diagnosis between embryonal and ependymal tumors at 3 T MRI. 61
29571787 2018
24
Prognostic Implications of Histological Clear Cells in High-Grade Intracranial Ependymal Tumors: A Retrospective Analysis from a Tertiary Care Hospital in Pakistan. 61
29682026 2018
25
Neoplastic Myelopathies. 61
29613896 2018
26
Survival of Ventricular and Periventricular High-Grade Gliomas: A Surveillance, Epidemiology, and End Results Program-Based Study. 61
29258929 2018
27
EANO guidelines for the diagnosis and treatment of ependymal tumors. 61
29194500 2018
28
Unedited microneurosurgery of a pineal region ependymoma. 61
30687571 2018
29
Recent Advances in the Classification and Treatment of Ependymomas. 61
28795287 2017
30
Lymph node metastasis of presacral ependymoblastoma in a young child. 61
28215462 2017
31
Pediatric Ependymoma: A Proteomics Perspective. 61
28387652 2017
32
Recent advances in subtyping tumors of the central nervous system using molecular data. 61
27893285 2017
33
Novel fusion genes and chimeric transcripts in ependymal tumors. 61
27401149 2016
34
Genetic differences on intracranial versus spinal cord ependymal tumors: a meta-analysis of genetic researches. 61
27637901 2016
35
Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. 61
26990854 2016
36
Spectrum of primary intracranial tumors at a tertiary care neurological institute: A hospital-based brain tumor registry. 61
27147159 2016
37
Chemotherapy for intracranial ependymoma in adults. 61
27108407 2016
38
Prognostic factors in ependymal tumors: Molecular biology trumps histopathology. 61
26954808 2016
39
Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. 61
26113311 2016
40
Histologic classification of gliomas. 61
26948349 2016
41
SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors. 61
26287936 2016
42
Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. 61
27390862 2016
43
Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity? 61
25795305 2015
44
Cytoplasmic 5-Lipoxygenase Staining Is a Highly Sensitive Marker of Human Tumors of the Choroid Plexus. 61
26185315 2015
45
Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. 61
26251808 2015
46
Establishment and maintenance of a standardized glioma tissue bank: Huashan experience. 61
24929994 2015
47
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. 61
25965575 2015
48
NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma. 61
25775275 2015
49
Ependymal tumors with oligodendroglioma like clear cells: Experience from a tertiary care hospital in Pakistan. 61
26664928 2015
50
Characteristics of childhood glial tumors, management approaches and life expectancy of the patients. 61
25261659 2014

Variations for Malignant Ependymoma

Expression for Malignant Ependymoma

Search GEO for disease gene expression data for Malignant Ependymoma.

Pathways for Malignant Ependymoma

Pathways related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 PLA2G5 GFAP EGFR
2 11.18 NF2 MGMT EGFR
3
Show member pathways
10.83 YAP1 GFAP EGFR

GO Terms for Malignant Ependymoma

Biological processes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of stem cell proliferation GO:0072091 9.16 YAP1 NF2
2 response to cobalamin GO:0033590 8.96 RELA EGFR
3 response to organic cyclic compound GO:0014070 8.92 RELA MGMT IDH1 EGFR

Sources for Malignant Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....